May 15, 2025

The American College of Radiology® (ACR®) filed comments May 7, with the U.S. Department of Commerce recommending that contrast media and radiopharmaceuticals be excluded or deferred from tariff impacts until greater domestic supplies are available.  

ACR’s comments were in response to a request for comments regarding Section 232 national security investigation of pharmaceuticals and ingredients issued by Commerce’s Bureau of Industry and Security (BIS). Section 232 allows the imposition of tariffs on imports that threaten national security. Pharmaceuticals and pharmaceutical ingredients are among several topics being considered by BIS.

The College indicated that contrast media and radiopharmaceuticals are integral components of medical procedures administered by qualified healthcare providers, often without alternative products, and should therefore be excluded or deferred. 

For questions, contact Michael Peters, ACR Senior Director, Government Affairs. 

Related ACR News

  • AI Effect on Clinical Practice

    The 2025 SIIM-ACR Data Science Summit brought together leaders in radiology, informatics and healthcare artificial intelligence to explore how AI is reshaping clinical practice.

    Read more
  • Scope of Practice Expansion Bills Become Law in Oklahoma

    Two harmful scope of practice expansion bills in Oklahoma, House Bill (HB) 2298 and HB 2584, recently became law after the state legislature voted to override Gov. Kevin Stitt’s (R) executive decision to veto the bills.

    Read more
  • ACR Advocacy for Members Continues in No Surprises Act Case

    The American College of Radiology® (ACR®) continues its advocacy in the surprise patient billing arena.

    Read more